Drs Rini, Balar, and Plimack look at the role of immunotherapy in 2 patients with advanced bladder cancer.
This activity is intended for oncologists, urologists, surgeons, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to discuss the recent advances in the use of immunotherapy for bladder cancer
Approximate Time to Complete: 30 minutes
Course Available Beginning: Sep. 22, 2017
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the identification of what line of treatment emerging immune checkpoint inhibitors may be used in patients with bladder cancer
- Have increased knowledge regarding the way programmed death-ligand 1 status may affect treatment selection and a patient's potential clinical response to immune checkpoint inhibitor
- Have greater competence related to recognizing evidence-based treatment options in patients with advanced bladder cancer